Ultra-low coverage genome-wide association study - insights into gestational age using 17,844 embryo samples with preimplantation genetic testing

Shumin Li[1,#], Bin Yan[1,#], Thomas K.T. Li[6,#], Jianliang Lu[1], Yifan Gu[4,5], Yueqiu Tan[4,5], Fei Gong[4,5], Tak-Wah Lam[1], Pingyuan Xie[2,3,*], Yuexuan Wang[1,7,*], Ge Lin[3,4,5,*], Ruibang Luo[1,*]

[1] Department of Computer Science, The University of Hong Kong, Hong Kong, China
[2] Hunan Normal University School of Medicine, Changsha, 410013, Hunan, China
[3] National Engineering and Research Center of Human Stem Cell, Changsha, Hunan, China
[4] NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Science, Institute of Reproductive and Stem Cell Engineering, Central South University, Changsha 410008, Hunan, China
[5] Clinical Research Center for Reproduction and Genetics in Hunan Province, Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha 410013, Hunan, China
[6] Department of Obstetrics & Gynecology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
[7] College of Computer Science and Technology, Zhejiang University, Hangzhou, China

[#] These authors contributed equally to this work
[*] To whom correspondence should be addressed: Ruibang Luo, Email: rbluo@cs.hku.hk, Ge Lin, Email: linggf@hotmail.com, Yuexuan Wang, Email: amywang@hku.hk, Pingyuan Xie, Email：plainxie192@126.com

Abstract

Background: Very low coverage (0.1 to 1x) whole genome sequencing (WGS) has

become a promising and affordable approach to discover genomic variants of human

populations for Genome-Wide Association Study (GWAS). To support genetic

screening using Preimplantation Genetic Testing (PGT) in a large population, the

sequencing coverage goes below 0.1x to an ultra-low level. However, its feasibility and

effectiveness for GWAS remains undetermined.

Methods: We devised a pipeline to process ultra-low coverage WGS data and

benchmarked the accuracy of genotype imputation at the combination of different

coverages below 0.1x and sample sizes from 2,000 to 16,000, using 17,844 embryo

PGT with approximately 0.04x average coverage and the standard Chinese sample

HG005 with known genotypes. We then applied the imputed genotypes of 1,744

transferred embryos who have gestational ages and complete follow-up records to

GWAS.

Results: The accuracy of genotype imputation under ultra-low coverage can be

improved by increasing the sample size and applying a set of filters. From 1,744 born

embryos, we identified 11 genomic risk loci associated with gestational ages and 166

genes mapped to these loci according to positional, expression quantitative trait locus

and chromatin interaction strategies. Among these mapped genes, *CRHBP, ICAM1* and

OXTR were more frequently reported as preterm birth related. By joint analysis of gene

expression data from previous studies, we constructed interrelationships of mainly

CRHBP, ICAM1, PLAGL1, DNMT1, CNTLN, DKK1 and *EGR2* with preterm birth,

infant disease and breast cancer.

Conclusions: This study not only demonstrates that ultra-low coverage WGS could

achieve relatively high accuracy of adequate genotype imputation and is capable of

GWAS, but also provides insights into uncovering genetic associations of gestational

age trait existed in the fetal embryo samples from Chinese or Eastern Asian populations.

Keywords: Ultra-low coverage Whole Genome Sequencing, Imputation, Single

Nucleotide Polymorphisms, Genome-Wide Association Study, Gestational Age,

Preterm Birth

Background

Detection and characterization of genetic variants associated with traits and diseases are fundamental to the study of human genetics. Genome-Wide Association Study (GWAS) is an approach widely used in genetic research that aims to decode the associations of specific genetic variations with particular diseases or traits in sample populations. In the past decade, GWAS has facilitated discovery of over one hundred thousand variants associated with complex traits in human (1). Whole-genome sequencing (WGS) has emerged as a dominant technology in GWAS because it enables one to generate a comprehensive view of the genomic variation landscape for not only a specific trait but also for common diseases. Thus, WGS-based approaches hold a significant advantage over genome-wide genotyping arrays or exome sequencing in the analysis of complete genetic variations. However, with a fixed budget, the high cost of sequencing many DNA samples is a limitation for GWAS (2-4). Recently, to reduce the cost of sequencing, a number of low (0.5-1x) or extremely low-coverage (0.1-0.5x) WGS has been carried out as an alternative method of genotyping (2, 5, 6). It is, however, unclear whether ultra-low coverage WGS (ulcWGS) below 0.1x data can capture enriched genetic variations across the entire allele frequency (AF) spectrum. When considering a balance between number of samples sequenced and sequencing read coverage, effective genotype imputation could provide more authentic DNA variants that would be helpful for genetic research.

Genotype imputation can be used to infer missing genotypes and to increase the accuracy of detecting genetic variants, such as single nucleotide polymorphisms (SNPs).

In general, performance of genotype imputation is largely affected by sample size, sequencing coverage, analysis methods, and other parameters (7). A main challenge to use very low coverage WGS is how to achieve an adequately accurate imputation for downstream analyses. Previous attempts have shown the efficiency of low coverage WGS, for example, a high r^2 of imputation accuracy observed by using 10 low coverage WGS (~0.5x) as compared to known genotypes (6). Pasaniuc et al. reported that the GWAS signals obtained from using 909 whole-exome sequencing (~0.24x) are comparable to using genotyping array (2). Gilly et al. found that more true association signals were identified by WGS (~1.0x) than the traditional array-based study (5). Using ulcWGS (0.06x-0.1x) with 141,431 samples from a Chinese genomic study, the accuracy of imputed genotypes reached 0.71 (8). Even though the distribution of genetic background from large number of samples is expected to compensate for the low sequencing coverages, it has never been determined how many samples are needed to achieve a relatively high accuracy. More importantly, lack of comparative data with coverages less than 0.05x results in the limited application of ulcWGS to GWAS.

Gestational age is an important complex trait associated with biological processes and human disease. Biologically, gestational duration plays a vital role in both mental and physical health of children at an age of five-year-old (9). Gestational age shorter than 37 weeks is categorized as Preterm Birth (PTB). Previous studies found the contribution of both the maternal and fetal genomes to variation of gestational ages (10-12). However, they focused on European and African samples by involving few samples from Chinese or Eastern Asian ancestries. Overall, biological mechanisms

underlying variation of gestational durations remain unclear, primarily because

insufficient maternal or fetal genotypes with widespread gestational ages have been

collected (13). Recently, Preimplantation Genetic Testing (PGT) with trophectoderm

biopsy for embryo aneuploidy screening has become a common practice in *in vitro*

fertilization (14, 15), and poses as an expectant source of genotypes for GWAS.

However, if the average sequencing coverage of PGT is even lower than the lowest

levels that have been reported in GWAS so far, it is necessary to examine whether such

PGT datasets are appropriately applied to GWAS.

In this study, we devised a pipeline for analyzing and applying the ulcWGS of

17,844 embryo samples for GWAS. Our result shows that a large sample size is

effective to increase the accuracy of genotype imputation even at an ultra-low coverage.

Furthermore, using the imputed genotypes of 1,744 embryos that were successfully

transferred and born with a widespread of gestational ages, we demonstrate the power

of using ulcWGS in GWAS and provides insights into understanding genetic

association of gestational age in embryos acquired from Chinese and East Asians.

Refreshing the lowest coverage used in GWAS, our finding also provides a foundation

for exploring the utilization of an even lower coverage for dissecting genotype-

phenotype associations.

Methods

Samples and sequencing coverage

The whole PGT dataset of 17,844 embryos was from the Clinical Research Center for

Reproduction and Genetics in Hunan Province, Reproductive and Genetic Hospital of

China International Trust Investment Corporation - Xiangya. The protocol of embryo

culture and biopsy was published in a related study (16). Three WGA kits were applied

to the biopsied TE cells by following the manufactures' guides, including REPLI-g

Mini Kit (called MDA), WGA4 GenomePlex Single Cell Whole Genome

Amplification Kit (called dop-PCR) and Rubicon Genomics PicoPlex Single Cell

Whole Genome Amplification Kit (called PicoPlex). A 1-2 µg of the WGA product was

subjected to library construction and sequencing on the four platforms, including BGI-

Seq 500, Illumina MiSeq, Ion Proton, Ion Torrent (Additional file 1: Table S2).

Study design

We developed a three-step pipeline to carry out genotype imputation using ulcWGS

data and to perform GWAS of the detected SNPs (Fig. 1). Firstly, the raw reads of the

17,844 embryo samples were aligned to the hs37d5 reference genome. Sequencing

coverage of these embryo samples displays a distribution with an average coverage

0.04x (Additional file 3: Figure S1). To our best knowledge, it is below the coverage of

any dataset used previously for genotype imputation. After removing potential PCR

duplicates, the aligned reads were used to call population SNPs. Secondly, we

conducted genotype imputation on each individual sample at the called population

SNPs and assessed the genotyping accuracy based on the standard Chinese sample

HG005 with known genotypes from GIAB (Genome in a Bottle, NIST)(17). Last, we

applied the imputed genotypes from 1,744 born embryos with complete follow-up

records to GWAS and explored biological associations between the genetic variants

detected in the born embryos and their gestational ages.

Sequencing read processing and alignment

In the first step of Fig. 1, the raw reads of the PGT samples were delivered in two

types, fastq or BAM. For BAM data, we used bedtools (18) to extract the raw reads into

single-end fastq files. The raw reads of each sample were then aligned to the hs37d5

reference genome using BWA (19). BWA-mem was applied to samples sequenced by

the Ion Torrent with longer reads and "bwa aln" was used for the rest of the samples

with shorter reads. Samtools rmdup (20) was used to remove the potential PCR

duplicates.

Population SNP calling

In the population SNP calling stage, we modified the method of Liu et al. (8). The first

stage is to use log-likelihood estimation for AF estimation, and the second stage is to

use log-likelihood ratio test for determining allelic types. More details are described in

Additional file 2: Supplementary Methods.

SNP calls of the raw population were filtered following the rules, 1) calls that

overlapped with the 35-kmer problematic alignment regions in hs37d5 were removed

(21); 2) calls that overlapped with regions with ENCODE mappability uniqueness

score unequal to 1 were removed (22), tool "bigWigToBedGraph" used afterward to

convert the bigwig into bed format) (23).

Genotype imputation

We used STITCH (24) version 1.5.7 for genotype imputation. The ancestral haplotypes

number k was set as 20, the assumed number of generations $nGen$ was set to 2000, and

the reads were binned into windows with *gridWindowSize* 10000. The *diploid* mode in

STITCH was used. Although using a reference panel is optional in STITCH, we used

the IMPUTE2 1000 genome haplotypes phase 1 reference panel as it improves the

accuracy of imputation when the sample size is small. With sample size larger than

10,000, the improvement was not significant. All parameters were optimized by

maximizing the r^2 of the estimated AFs between imputation and population SNP

calling in a randomly chosen 5 Mbp genomic region (chr3:180-185Mbp). When

applying STITCH to the whole genome, we divided the genome into 5 Mbp windows

with a 500 Kbp overlap between two windows.

For benchmarking, seqtk was used to subsample the HG005 Illumina WGS raw

reads to 0.01x-0.1x (Paired-end 250bp, 300-fold). We aligned the reads to hs37d5 by

using the same pipeline as used in the embryo samples. Because a computer takes a few

years to impute whole genome with tens of thousands of samples, we worked on only

chromosome 1, the longest one in human. The genotype imputation was benchmarked

according to 80 combinations of the 10-scale coverages of HG005 with 8 sizes of our

samples from 2,000 to 16,000, respectively.

All bi-allelic SNPs with MAF $\geq$ 0.01 found in chromosome 1 with the population

SNP calling from the 17,844 samples are included for genotype imputation. We used

the 167,814 SNPs both in our SNP callset and HG005 known genotypes for

benchmarking. The imputed genotypes were compared to the truth released by GIAB

for estimating the imputation accuracy. Then, genotype imputation was applied to all

17,844 embryo datasets at the 31,622,332 bi-allelic sites with MAF ≥ 0.01 found in

population SNP calling. The entire imputation process spent 19 days and used 15

machines with 16 cores (two 8-core Intel Xeon Silver 4108 CPU). Two filters "INFO

score ≥ 0.4 and HWE *p*-value >1e-6" were applied to select the imputed genotypes.

Genome-wide association study (GWAS)

To conduct GWAS, we used score statistics (25) that is implemented in ANGSD (26).

Variants satisfying four conditions were selected as inputs, including 1) known in

dbSNP150, 2) MAF ≥ 0.01, 3) INFO score ≥ 0.4, and 4) HWE *p*-value > 1e-6. To

remove biases, we specified 16 covariates for ANGSD, 8 most significant principal

components calculated from the inputs of PCA (Additional file 2: Supplementary

Methods), and 8 clinical records including maternal age, maternal BMI, fetal sex, either

parent with single-gene disease, either parent with chromosome abnormality, multiple

pregnancy, preeclampsia and gestational diabetes of mellitus. Except the default

parameters, we set *minHigh* to 15 (requiring at least 15 high credible genotypes from

the input) instead of 10 to achieve better accuracy with a large sample size. ANGSD

did not create an output beta-coefficient, so we followed the ideas of Skotte et al. (25)

by incorporating the genotype probabilities and all 16 covariates into a linear regression

model, with the gestational age as a response variable. The effect size was calculated

by the coefficient of genotypes.

Independent SNPs and genomic risk loci

The significant SNPs from our GWAS were mapped to genomic risk loci using FUMA pipeline (27) and the LD information of 1000G EAS variants (28). We first defined "independent significant SNP", a SNP that meets genome-wide significance level (p value $\leq 4.515e - 8$) and is independent of other significant SNPs (with LD $r^2 <$ 0.6). FUMA also generated a set of lead SNPs with low LD and with other ($r^2 < 0.1$) from the independent significant SNPs. The genomic risk loci were identified by starting from these lead SNPs and through iteratively merging related genomic regions to them according to FUMA's rules.

Also, the FUMA pipeline sorted out a set of candidate SNPs from our inputs that meets one of two conditions, 1) the independent significant SNPs and 2) SNPs that are linked to the independent significant SNPs (with LD $r^2 \geq 0.6$). For condition 2, the SNPs can be from our imputed genotypes if p value below 0.05 or from the reference panel of 1000G EAS. ANNOVAR was used to annotate the candidate SNPs (29).

Functional annotation of the mapped genes

DAVID online tool (30) was used to analyze the enrichment of Gene Ontology (GO) biological processes and KEGG pathways for the coding genes mapped to the risk loci.

Gene mapping

We used three gene-mapping strategies provided by FUMA (27), including positional, expression quantitative trait locus (eQTL) and chromatin interaction. For positional

mapping, ANNOVAR annotations were used. The candidate SNPs were mapped to the

nearest genes within a maximum 10 Kbp distance. For eQTL mapping, expression data

of all tissue types in GTEv6, GTEv7, and GTEv8 (31) were used. We required False

Discovery Rate (FDR) < 0.05 and p value <0.001 for a valid eQTL mapping. All

chromatin interaction data in FUMA were used (32-35). The promoter was set to

upstream 2000 bp to downstream 500 bp of transcriptional starting sites. We required

FDR < 1e-6 for a valid chromatin interaction mapping.

Analysis of genome-wide mRNA expression data

We first extracted the genome-wide microarray and RNA-seq data of human mRNA

expression from GEO/NCBI database. The mRNA data includes three subsets in

maternal PTB, infant PTB and breast cancer (Additional file 1: Table S8). Based on the

normalized expression data provided by the database, we analyzed differentially

expressed genes (DEGs) between different conditions, including 1) PTB vs. normal

term, 2) BPD or sepsis vs. infant without BPD or sepsis, and 3) breast cancer vs. control

samples. For microarray platform-based data, we used the *limma* package in R

programming language and conducted empirical Bayes moderated t-test. DEGs were

detected with a fold change above 1.5 and p value below 0.05. For RNA-seq data with

raw counts, we utilized the Edge-R method to identify DEGs. The DEGs are listed in

Additional file 1: Table S9.

Results

Benchmarking genotype imputation using the ultra-low coverage sequencing data of 17,844 embryos and HG005

We estimated the accuracy of the imputed genotypes from the SNPs of chromosome 1 both called in our 17,844 samples and the known genotypes in HG005. The genotype imputation was benchmarked according to 80 combinations of the 10-scale coverages of HG005 with 8 sizes of our samples. A monotonic increase in accuracy with sequencing coverage was observed (Fig. 2a), consistent with previous studies (2, 24). The accuracy for sample size of 2,000 stayed at around 0.48 under all sequencing coverages. But for a larger sample size of 16,000, its accuracy increased from 0.48 at 0.01x to 0.66 at 0.1x. This result suggests that at ultra-low coverages, increase in sample size could obtain higher accuracy (Additional file 1: Table S1). In general, a lower coverage with a larger sample size results in better performance than a higher coverage with a smaller sample size. For example, the genotype accuracy at 0.05x with 14,000 samples versus 0.1x with 4,000 embryos was 0.61 versus 0.55. A larger sample number is therefore more efficient in optimizing genotype imputation than increasing sequence coverage. It is also noticed that at the two lowest coverages in our experiments, the contribution of increasing sample size was not significant and the accuracy plateaued at 0.52 (0.01x) and 0.55 (0.02x). Using the same datasets, we evaluated allele accuracy that relaxed zygosity correctness from genotype accuracy. The corresponding accuracies were much better (increased to 0.7 and higher) while maintaining the same trend with increasing sample size and coverage (Fig. 2b). Therefore, when the

genotypes are incorrectly imputed for some SNPs, the non-reference allele could be

correctly detected.

We next examined several important quality metrics that are widely used to filter

falsely imputed genotypes. The INFO score of IMPUTE2 style (36) denotes the

certainty of an imputed genotype and has been accepted as a quality metric of

imputation. For a combination of 0.04x coverage with 16,000 samples, we

benchmarked ten different INFO score thresholds from 0.1 to 1.0 and detected

corresponding SNPs. As increase in the INFO scores, we observed a consistent increase

in genotype accuracy from ~0.60 to 0.99, but a rapid decrease in number of SNPs that

meet these thresholds (Fig. 3a). Thus, INFO score could act as an effective metric to

evaluate the accuracies at ultra-low coverage, but its thresholds should be meticulously

chosen in order to retain sufficient SNPs. Effect of MAF scores on genotype accuracy

of HG005 were then tested as a potential metric. We divided the genotyping results at

different sequencing coverages (sample size fixed to 16,000) into bins of MAF ranges

(0.01 MAF a bin) and calculated the genotype accuracy each bin. The genotype

accuracy increased rapidly from MAF 0 to 0.05 and reached a turning point at 0.05.

After this point, the accuracy became slow increasing (Fig. 3b). However, even for the

most common SNPs (MAF 0.4~0.5), the accuracy was converged at ~70%. The

accuracy of the two lowest coverages 0.01x and 0.02x fluctuated especially at low MAF

cutoffs. Because such fluctuation was not observed during INFO testing, MAF might

not be a reliable metric to change genotype accuracy at ultra-low coverage. In

subsequent analyses, we followed the common practice to use SNPs with MAF ≥ 0.01

for GWAS. Finally, we combined HWE *p*-values with INFO scores as a filter but without losing too many SNPs. HWE *p*-values could evaluate the probability of the imputed genotype at a certain SNP that is significantly different from the expectations by Hardy-Weinberg Equilibrium. We summarized the genotype accuracy of different combinations of INFO scores and HWE *p*-value cutoffs in Table 1. When INFO scores were set above 0.4, the accuracies of genotype and allele were 70.0% and 83.4%, respectively, with 48,176 SNPs left. The "INFO score ≥ 0.4 and HWE *p*-value >1e-6" resulted in an increased accuracy 71.5%, with 28773 SNPs left. Thus, our GWAS utilized this setting, "INFO score ≥ 0.4 and HWE *p*-value >1e-6" as filtering criteria.

To summarize our benchmarking results for future study on ulcWGS, we built a regression model (Formula 1) to calculate the expected genotype accuracy using sequencing coverage and sample size as inputs.

$$acc = 2.227 * c + 8.937e^{-6} * s + 0.494 \ (c \geq 0.01, s \geq 4000) \qquad (1)$$

where *acc* is the expected genotype accuracy, *c* denotes the sequencing coverage, *s* denotes the sample size. The model has a r^2 of 0.874 (Additional file 3: Figure S2).

GWAS of gestational ages using 1,744 born embryos

With the solid foundation laid out in the previous section, we have obtained sufficient good quality SNPs for GWAS. Among the 17,844 sequenced embryos, 1,744 were transferred and gave birth to a baby. The gestational age of all 1,744 born embryos are well documented and thus were chosen for biological associated study. We revised the population SNP calling method used in Liu et al. (8). A total of 151,793,444 SNPs were detected and of 141,718,305 are bi-allelic. The MAF spectrum bi-allelic novel and

known variants in dbSNPv150 (37), 1000G (28) and gnomAD (38) is shown in

Additional file 3: Figure S3a. The transitions/transversions ratio for "all bi-allelic SNPs"

and "bi-allelic SNPs known in dbSNPv150" were 3.05 and 3.58, respectively. Pearson

correlation coefficient of the non-reference AFs between the 301 Chinese samples in

1000G (so-called 1000G CHN (28)) and the corresponding SNPs obtained in our

dataset was 0.986 (Additional file 3: Figure S3b). This result supports a strong

correlation between the two datasets, and high confidence of the known variants used

in our analysis. We also performed genotype imputation at bi-allelic population SNPs

with MAF $\geq$ 0.01. Pearson correlation coefficient was 0.985, showing a high

consistency between the estimated AFs in population SNP calling and in imputation.

Three different whole genome amplification (WGA) methods and four different

sequencing platforms were used in the PGT dataset (Additional file 1: Table S2). It is

not uncommon that large number of samples may use multiple sequencing platforms

and WGA. Removing these unrelated covariates from GWAS as much as possible is

essential especially when the sequencing coverage is ultra-low. Such covariates should

be detected and disregarded in GWAS. We applied Principal Component Analysis (PCA)

to the imputed genotypes of SNPs with MAF $\geq$ 0.05 among all 17,844 embryo samples

(Additional file 2: Supplementary Methods, Additional file 3: Figure S4a). The first and

second principal components distinguish the differences of sequencing platforms

(Additional file 3: Figure S4b) and of WGA methods (Additional file 3: Figure S4c).

Therefore, we used the top eight principal components and eight other clinical records

as covariates in GWAS. PCA was also applied to the GWAS samples and the top

principal components were included in the subsequent analyses as covariates for

removing the biases.

We used the state-of-the-art one-stage GWAS strategy (39) to analyze the

1,107,198 imputed SNPs in the 1,744 transferred and born embryo samples with

complete follow-up records. The distribution of gestational ages shown in Additional

file 3: Figure S5 include 162 preterm deliveries (gestational age < 37 weeks), 42 early

preterm deliveries (gestational age <34 weeks), and 8 very early preterm deliveries

(gestational age <28 weeks). The gestational ages were standardized by z-score and

incorporated as a quantitative trait.

A total 1,107, 198 SNPs with imputed genotypes were selected for GWAS that

are in accord with, 1) MAF ≥ 0.01, 2) known in dbSNPv150, and 3) passed the filter

"INFO score ≥ 0.4 and HWE *p*-value >1e-6". The Q-Q plot shows a large deviation of

the observed p values from the null hypothesis (Additional file 3: Figure S6). The

linkage disequilibrium score regression (LDSC) software package (40) with 1000G

EAS reference was used to estimate $\lambda_{GC} = 0.992$, mean $\chi^2 = 1.012$. The LD score

regression intercept was 0.952, standard error = 0.021, indicating that the population

stratification and other factors were well-controlled. We identified 40 significant SNPs

satisfying Bonferroni-corrected significant levels of 4.515e-8. The Manhattan plot

shows the distribution of the detected SNPs cross all chromosomes (Fig. 4a, Additional

file 1: Table S3).

We used FUMA (27) pipeline for GWAS downstream analysis. First, FUMA

generated a set of candidate SNPs and the 11 independent SNPs (Additional file 1:

Table S4). By annotation, most of the SNPs are located and enriched in intergenic and

intronic regions (Fig. 4b), which is similar to the previous study (41). Specifically, there

are 11 SNPs located in exons (0.8% of total), and 4 of them are non-synonymous SNPs

(Additional file 1: Table S5). Additionally, we observed the distribution of regulatory

elements and chromatin states with the candidate SNPs (Additional file 3: Figure S7).

According to RegulomeDB scores assigned to each candidate SNP, 1.09% SNPs were

classified as likely to affect regulator binding (score 2a and 2b) and 0.21% as likely to

affect regulator binding and linked to expression of a gene target (score 1d and 1f).

These proportions of SNPs hold a relatively high likelihood to affect the regulatory

elements along noncoding regions. Second, we identified 11 leading SNPs from their

corresponding genomic risk loci by FUMA. Fig. 4e shows the DNA length, number of

SNPs and mapped genes of these risk loci. The zoom in locus plot of the 11 risk loci

are shown in Additional file 3: Figure S8. Of 4 risk loci were reported to be associated

with refractive astigmatism, adolescent idiopathic scoliosis, glomerular filtration rate,

among others, indicating a possible connection of these diseases or traits with PTB

(Additional file 1: Table S6).

By integrating strategies positional, eQTL and chromatin interaction mappings,

we identified a total of 166 genes mapped to the 11 risk loci, including 48 and 19 genes

from two and three strategies, respectively (Fig. 4c, Additional file 1: Table S7). There

were 24 genes detected within or less than 10 Kbp from the candidate SNPs and 7 of

them were shown in Fig. 4a based on the location of the genomic risk loci. Importantly,

CNTLN was reported as a PTB related gene (42), and *PIN1* involves inhibition of breast

cancer (43). A Circos plot shows the graphic distribution of the mapped genes via eQTL

and chromatin interaction, and their links with the genomic risk loci (Fig. 4d). The

breakdown of each chromosome is shown in Additional file 3: Figure S9. Even though

not within any risk loci, *CRHBP* was linked through chromatin interaction mapping to

two loci, chr5:75101342-75164623 and chr5:78251511-78271282. Enrichment

analysis of DEGs in 30 tissue types in GTEx v8 (44) exhibits significant overexpression

of the mapped genes in both ovary and uterus (Additional file 3: Figure S10a). The

gene-set enrichment analysis also indicates their association with the immune system,

breast cancer and transcriptional regulation (Additional file 3: Figure S10b).

Association of the 166 mapped genes from GWAS with preterm birth,

infant disease and breast cancer

GWAS of gestational age related PTB has been implicated in biological functions that

include immune response, inflammatory response, and coagulation factors (11, 45-47).

We compared our 166 mapped genes with reported PTB markers by collection of 8

published resources, here classed to 3 PTB sets, including dbPTB from Sheikh et al.

(48) and Uzun et al (49), PTB-merged from 5 data resources (10), and PNAS-identified

DEGs of PTB in 2019 (10). We found that *CRHBP, EMR1, ICAM1, MBL2, OXTR,* and

THBS4 have been reported in at least 2 PTB sets. Specifically, *ICAM1* was present in

all 3 sets and 6 data resources, and both *CRHBP* and *OXTR* in 5 resources (Additional

file 1: Table S7). In addition, there were 8 genes overlapped with 1 PTB set (Fig. 5a).

This result pinpoints a relationship of the detected risk loci with PTB, and possible roles

of the overlapped genes in PTB. There are totally 1,930 genes reported as PTB-related;

however, only 50 were frequently recognized by at least 5 data resources, hereafter

referred to as PTB marker genes (Additional file 1: Table S7). The 50-PTB marker set

was significantly enriched with inflammatory and immune response related processes

or pathways (Fig. 5b). Similarly, those PTB genes that overlapped with 3 or 4 resources

mainly participate in the same biological functions. The PTB-related genes listed at Fig.

5a involve immune response (*EMR1, ICAM1, PTPRZ1* and *MBL2*), inflammatory

response (*CRHBP, ICAM1, PTPRZ1* and *MBL2*), coagulation (*MBL2*), apoptosis

(*PLAGL1*) and cell adhesion (*ICAM1* and *THBS4*), emphasizing their associations with

PTB.

To determine the relationship between the mapped genes and PTB, we first

analyzed the DEGs between maternal PTB and normal term birth based on six

published datasets of genome-wide gene expression (Additional file 1: Tables S8 and

S9). Significant overexpression of *CRHBP* and *OXTR* were identified in two datasets,

while overexpressed (*ICAM1, EGR2,* and *PLAGL1*) and underexpressed (*THBS4*)

genes were present in one dataset (Table 2). Another *DKK1* expressed higher levels

above 2.0-fold in two datasets, suggesting its importance in PTB. Then, we analyzed

four infant PTB datasets of gene expression, and found differentially increased

expression of *ICAM1, CRHBP, DKK1, EGR2,* and *PLAGL1,* consistent with maternal

PTB. In contrast, significantly underexpression of *THBS4, PIN1* and *GCNT4* was

commonly detected by maternal and infant subgroups (Table 2). It is also noticed that

DNMT1 shows increased expression in both fetal and maternal groups (Table 2). DNA

methylation was suggested to involve generation of early PTB (10); however, the role

of *DNMT1* as a DNA methyltransferase in PTB has not been determined yet. This

analysis provides evidence that these mapped DEGs above including *DNMT1* are

associated with both maternal and infant PTB. Relatively, *OXTR* seems to be related to

only maternal factor. A heatmap of mRNA expression shows clustering of 6 expression

profile cross PTB and normal term conditions (Fig. 5c). Two clusters display distinct

expression patterns of these PTB genes.

It is well known that bronchopulmonary dysplasia (BPD) is the most common

respiratory disorder among children born preterm (50, 51). The pathogenesis of BPD

involves multiple prenatal and postnatal mechanisms affecting the development of

immature lung. Also, neonatal sepsis is associated with severe morbidity and mortality

during the neonatal stage. The incidence of late-onset sepsis increases with increase in

survival rate of preterm and low weight babies (52). Thus, we examined the possible

relationship of the 166 genes with infant BPD and sepsis by analyzing gene expression

data derived from samples of preterm infants (Additional file 1: Table S8). We first

identified differentially increased expression of *CRHBP, ICAM1* and *EGR2* under PTB

of maternal & infant and BPD conditions, but differentially decreased expression of

DKK1 (Table 2). Under sepsis condition, differentially overexpressed *CNTLN, ICAM1,*

and *PLAGL1* in PTB were consistently observed. By contrast, *GCNT4* expression was

always significantly decreased under maternal and infant subpopulations. The gene

clustering shows diversity of gene expression across different samples with infant PTB;

however, these up-regulated genes were grouped together (Fig. 5d), supporting the idea

that BPD or sepsis induces the change in these PTB genes.

Breast cancer is one of the most frequently diagnosed malignancies observed

during pregnancy. It often presents characteristics of high malignancy and are hormone

receptor negative like Estrogen receptor (ER)-, HER2+ or triple negative breast cancer

(TNBC). We collected gene expression data mainly presenting three subtypes of breast

cancer, TNBC, HER2+ and ER or Progesterone receptor (PR) (Additional file 1: Table

S8). By analysis of DEGs, we detected the expression of PTB related genes *DKK1,*

ICAM1, DKK1, EGR2, PLAGL1, GCNT4 and *THBS4* in all three subtypes. Increased

ICAM1 and decreased *PLAGL1* were consistently identified in these datasets (Table 2).

In fact, *ICAM1* has been reported as TNBC markers (53) and acts as prognostic

molecule of breast cancer (54). Both *ICAM1* and *DKK1* could increase expression in

TNBC cells (55). However, other PTB related genes do not display similar changes in

expression under the cancer subtypes. For example, *OXTR* was detected by only one

dataset of ER+/-, while *CRHBP, EMR1, PIN1* and *MBL2* were not found among any of

the subtypes. Conversely, underexpression of *PLAGL1* and *GCNT4* were found in all

three types of breast cancer. In addition, overexpression of *DNMT1* was observed in

TNBC and HER2+ subtypes, that validates its oncogenic roles in breast cancer and drug

target of TNBC (56, 57).

To identify further interactions between the selected PTB genes from Table 2 and

the top 50 PTB markers, we calculated Pearson correlation coefficient by comparing

their gene expression of maternal and infant PTB, BPD and sepsis subsets, respectively.

We built the corresponding co-expression networks of the PTB genes (Additional file

3: Figure S11). Clearly, the co-expressed genes involve immune and inflammatory

responses, coagulation, as well as apoptosis, angiogenesis, among others. We then

constructed the networks cross different subpopulations. As shown in Fig. 6a, the PTB

genes could involve both maternal and infant PTB processes, especially *ICAM1*,

PLAGL1, EGR2 and *CRHBP* that link to TLR4, a known preterm marker associated

with immune and inflammatory processes (58). Similarly, co-expression interactions of

these genes with the top PTB markers were observed under maternal PTB and infant

BPD (Fig. 6b). Both *OXTR* and *PIN1* only display gene correlations under maternal

PTB, whereas *MBL2* only correlates under infant PTB. This analysis indicates that the

predicted PTB-related genes including *ICAM1*, *CRHBP*, *PLAGL1, EGR2, CNTLN,* and

DKK1, play an important role in preforming biological activities associated with PTB,

infant disease, possibly breast cancer, due to the gestational age-induced.

Discussion

Low or very low coverage sequencing data have been increasingly used in discovery of

genetic variation and GWAS. However, if the coverages are further decreased to

extremely ultra-low levels, how many samples are required to obtain a relatively high

accuracy of genotype, and whether these samples can be appropriately applied to

GWAS. To address this challenge, we used 17,844 PGT datasets of embryo samples

with an average of 0.04x coverage and achieved genotype imputation performance

comparable to those using low coverage samples. We first demonstrate that increase in

number of ulcWGS samples is more efficient than changing sequencing coverages and

indicates the ability of such ultra-low coverage PGT samples to obtain adequate

accuracy of phenotypes. Furthermore, we found that INFO score and HWE *p*-value are

effective to act as filters to improve the accuracy at ultra-low coverages while

meanwhile keep enough SNPs for downstream analyses. To our best knowledge, the

samples used in this study hold the lowest average WGS coverage for GWAS so far,

and our study provides a framework for guiding other researchers who work on

ulcWGS data.

Gestational age is a multi-factor phenotype involved in maternal and fetal

biological activities (59). To investigate effects of the fetal genome on gestational age,

we used the imputed genotypes of 1,744 born embryo samples, a cohort of samples who

successfully gave birth after *in vitro* fertilization. From the 166 genes mapped to the 11

genomic risk loci, we identified a set of the PTB-related genes that were previously

reported (12, 59). *CRHBP, ICAM1,* and *OXTR* are primary representative genes

showing evidence of genetic association with gestational age among our samples.

CRHBP is an important gene in maternal and fetal gestation that could regulate the

pregnancy length by increasing/decreasing the concentration of CRH (60, 61). *ICAM1*

involves disease induced PTB during pregnancy (62-64). Oxytocin signaling is

mediated by Oxytocin receptor (*OXTR*), which is related to gestational age (65). We

validated these predicted PTB genes by analysis of DEGs from maternal and infant

PTB subpopulations.

PTB is neonatal birth occurring before 37 weeks of gestation age and is a leading

cause of infant morbidity and mortality. Understanding of genetic and molecular

mechanisms of PTB and its association with gestation duration is currently insufficient.

Recently, Zhang et al. reported replicable loci in six genes (*EBF1, EEFSEC, AGTR2,*

WNT4, ADCY5 and *RAP2C*) associated with gestational duration (12). This study

identified 3 genes (*EBF1, EEFSEC* and *AGTR2*) strongly associated with PTB in a

European ancestry cohort of 43,568 women. However, we did not detect such 6 genes

from the reported PTB markers and only identified them as DEGs from few published

datasets of PTB. This could be due to the heterogeneous sources of samples used in

different PTB studies or be explained in part by the genetic complexity of incomplete

gestation induced PTB complications. Here, we collected almost 2,000 PTB-related

genes from previous PTB studies. The differences in study design, source and subtype

of samples, and statistical methods would be important factors that could account for

the diversity of PTB variants and genes among the various studies. Considering the

possible association of PTB with other traits, we compared differential gene programs

on multiple phenotypes between mother and infant reported in previous studies, and

demonstrated a high risk of *CRHBP, ICAM1, DNMT1, CNTLN, PLAGL1, DKK1* and

EGR2 with PTB among our sample cohorts of Chinese or Eastern Asian ancestry. To

support this finding, we reconstructed co-expressive networks linking the PTB-related

genes in GWAS with the reported PTB markers. Indeed, the correlated PTB genes are

mainly involved in immune & inflammation related processes and signaling pathways,

as well as coagulation factors. Thus, these findings have biological implications for

dissecting genetic associations of gestational factors with disease or traits in different

human ancestries.

Pregnancy is associated with an increased risk of developing breast cancer (66).

Although several reports indirectly described relationship between breast cancer and

PTB (67), evidence is still lacking. To determine whether a correlation exists between

PTB women and breast cancer pathogenesis, we compared differential expression of

the PTB related genes in PTB samples and three subtypes of hormone receptor-related

breast cancer samples. Although several DEGs were found in both PTB and cancer

subtypes, their expression patterns are not consistent. It perhaps is because of different

subtype of samples derived from heterogeneous populations, as well as different

phenotypes involved in the analyses. Nevertheless, our data provides additional

evidence that PTB might be related with breast cancer hormone-related subtypes. A

graphic overview of our results is summarized in Fig. 6c. We proposed interplays of

gestational age with PTB, fetal disease and breast cancer. The representative PTB genes

CRHBP, ICAM1, THBS4, DNMT1, CNTLN, PLAGL1, DKK1 and *EGR2* are likely

associated with these phenotypes by targeting immune and inflammatory response,

coagulation, and cell adhesion.

Conclusions

This study benchmarked the ability of ulcWGS to be used for genotype imputation. As

the first study using a large cohort of human embryo samples with ulcWGS, we

demonstrate its power and effectiveness in GWAS. We detected 40 significant SNPs

and 11 genomic risk loci that contains independent significant SNPs and are associated

with gestational age. From 166 genes mapped to the risk loci. We establish

interrelationships between the mapped genes and maternal or infant diseases and

provide insights into understanding the genetic associations of gestational ages. Our

findings should expand current GWAS related to gestational duration and preterm trait

by including Chinese and East Asian samples and would therefore be helpful to future

research.

Supplementary Information

Additional file 1: Table S1. Genotype imputation performance at different ultra-low

coverages and sample sizes. **Table S2**. WGA methods and sequencing platforms used

in the PGT experiments. **Table S3**. The summary of 40 significant SNPs satisfying

Bonferroni-corrected significant levels of 4.526e-8 from 1,744 embryo PGT samples.

Table S4. The list of candidate SNPs. **Table S5**. Nonsynonymous SNPs that are

independent significant SNPs or in LD (r2>0.6) with one of the independent significant

SNPs. **Table S6**. The reported genomic risk loci from GWAS catalog that were detected

in our dataset. **Table S7**. A list of 166 mapped genes by positional, eQTL, and chromatin

interaction mappings. **Table S8**. Data sources of genome-wide mRNA expression in

Preterm birth, infant disease and breast cancer. **Table S9**. A list of the 166 mapped genes

that were also identified by differentially expressed genes (DEGs) derived from

analyzing the genome-wide gene expression datasets listed.

Additional file 2: Supplemental Methods

Additional file 3: Figure S1. Sequencing coverage statistics of the 17,844 embryos.

Figure S2. Visualizing the linear regression model for genotype accuracy prediction.

Figure S3. Quality control of SNP calling. Figure S4. Figure S4. Principal component

analysis of all 17,844 embryo samples. **Figure S5.** Distribution of gestational age in the

1,744 born embryo samples. **Figure S6.** Quantile-Quantile plot of the 1,107,198 studied

SNPs. **Figure S7.** Pie charts of the candidate SNPs. **Figure S8.** Zoom in locus plots of

the 11 genomic risk loci. **Figure S9.** Circos plots of chromatin interactions and eQTL

mapping. **Figure S10.** Gene set analysis of the 166 mapped genes. **Figure 11.** Co-

expression network of PTB-related genes in maternal and infant subtypes.

Abbreviations

WGS: whole genome sequencing; NGS: next-generation sequencing; GWAS:

genome-wide association study; bp: base pair; SNP: single nucleotide polymorphism;

PTB: preterm birth; PGT: preimplantation genetic testing; MAF: minor allele

frequency; LD: linkage disequilibrium; HWE: Hardy-Weinberg equilibrium; WGA:

whole genome amplification; PCA: principal component analysis; eQTL: expression

quantitative trait locus; FDR: false discovery rate; GO: gene ontology; BPD:

bronchopulmonary dysplasia; ER: Estrogen receptor; PR: Progesterone receptor;

HER2: human epidermal growth factor receptor 2; TNBC: Triple-negative breast

cancer; DEG: differentially expressed gene; AF: allele frequency. GIAB: Genome in a

Bottle; BWA: Burrows-Wheeler Aligner. GEO: Gene Expression Omnibus: NCBI:

National Center for Biotechnology Information.

Declarations

Ethics approval and consent to participate

All individual samples in the technical concordance cohort and clinical cohort, and

protocols used in this study have been reviewed and approved by the Institutional

Review Board (IRB) of China International Trust Investment Corporation - Xianngya

(IRB Reference No. LL-SC-2020-004). The need to obtain informed consent has been

waived by the IRB due to the study's retrospective nature. Following the regulations of

the Human Genetic Resources Administration of China, all genetic materials involved

in this study have been reviewed and approved by Ministry of Science and Technology

of the People's Republic of China (Approval No. [2022] GH1831). The experimental

methods were in accordance with the principles of the Helsinki Declaration.

Consent for publication

Not applicable

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article

and its additional files. The significant SNPs and candidate SNPs are listed in

Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA

expression datasets shown in Additional file 1: Table S8 was downloaded from Gene

Expression Omnibus (GEO)/National Center for Biotechnology Information (NCBI).

Funding

The study was supported by the Early Career Schema (27204518) of the Hong Kong

Research Grants Council for RL, partially by General Research Funding of Hong Kong

Research Grants Council (17113721) for RL and (17117918) for BY, by the University

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SL, RL and BY developed the computational pipeline and the algorithms. RL, GL, YW,

TKL, and TL designed the experiments. PX, YG, FG and YT contributed to the clinical

data collection. SL, BY, JL, YG and FG performed data processing and analysis. RL,

GL, SL, BY, PX and YW participated in drafting the manuscript. All authors read and

approved the final manuscript.

Acknowledgements

Not applicable

Reference

1. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. American journal of human genetics. 2017;101(1):5-22.

2. Pasaniuc B, Rohland N, McLaren PJ, Garimella K, Zaitlen N, Li H, et al. Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. 2012;44(6):631.

3. Wang Z, Chatterjee N. Increasing mapping precision of genome-wide association studies: to genotype and impute, sequence, or both? Genome Biology. 2017;18(1):118.

4. Quick C, Anugu P, Musani S, Weiss ST, Burchard EG, White MJ, et al. Sequencing and imputation in GWAS: Cost-effective strategies to increase power and genomic coverage across diverse populations. 2020;44(6):537-49.

5. Gilly A, Southam L, Suveges D, Kuchenbaecker K, Moore R, Melloni GEM, et al. Very low-depth whole-genome sequencing in complex trait association studies. Bioinformatics. 2019;35(15):2555-61.

6. Homburger JR, Neben CL, Mishne G, Zhou AY, Kathiresan S, Khera AV. Low coverage whole genome sequencing enables accurate assessment of common variants and calculation of genome-wide polygenic scores. Genome medicine. 2019;11(1):74.

7. Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nature reviews Genetics. 2010;11(7):499-511.

8. Liu S, Huang S, Chen F, Zhao L, Yuan Y, Francis SS, et al. Genomic Analyses from Non-invasive Prenatal Testing Reveal Genetic Associations, Patterns of Viral Infections, and Chinese Population History. Cell. 2018;175(2):347-59.e14.

9. Cronin FM, Segurado R, McAuliffe FM, Kelleher CC, Tremblay RE. Gestational Age at Birth and 'Body-Mind' Health at 5 Years of Age: A Population Based Cohort Study. PloS one. 2016;11(3):e0151222.

10. Knijnenburg TA, Vockley JG, Chambwe N, Gibbs DL, Humphries C, Huddleston KC, et al. Genomic and molecular characterization of preterm birth. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(12):5819-27.

11. Liu X, Helenius D, Skotte L, Beaumont RN, Wielscher M, Geller F, et al. Variants in the fetal genome near pro-inflammatory cytokine genes on 2q13 associate with gestational duration. Nature communications. 2019;10(1):3927.

12. Zhang G, Feenstra B, Bacelis J, Liu X, Muglia LM, Juodakis J, et al. Genetic Associations with Gestational Duration and Spontaneous Preterm Birth. The New England journal of medicine. 2017;377(12):1156-67.

13. Wadon M, Modi N, Wong HS, Thapar A, O'Donovan MC. Recent advances in the genetics of preterm birth. Annals of human genetics. 2019.

14. Brezina PR, Kutteh WH, Bailey AP, Ke RW. Preimplantation genetic screening (PGS) is an excellent tool, but not perfect: a guide to counseling patients considering PGS. Fertil Steril. 2016;105(1):49-50.

15. Huang L, Bogale B, Tang Y, Lu S, Xie XS, Racowsky C. Noninvasive preimplantation genetic testing for aneuploidy in spent medium may be more reliable

than trophectoderm biopsy. Proc Natl Acad Sci U S A. 2019;116(28):14105-12.

16. Tan Y, Yin X, Zhang S, Jiang H, Tan K, Li J, et al. Clinical outcome of preimplantation genetic diagnosis and screening using next generation sequencing. GigaScience. 2014;3(1):30.

17. Zook JM, Chapman B, Wang J, Mittelman D, Hofmann O, Hide W, et al. Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nature Biotechnology. 2014;32(3):246-51.

18. Quinlan AR. BEDTools: The Swiss-Army Tool for Genome Feature Analysis. Current protocols in bioinformatics. 2014;47:11.2.1-34.

19. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25(14):1754-60.

20. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-9.

21. Li H. FermiKit: assembly-based variant calling for Illumina resequencing data. Bioinformatics. 2015;31(22):3694-6.

22. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996-1006.

23. Kent WJ, Zweig AS, Barber G, Hinrichs AS, Karolchik D. BigWig and BigBed: enabling browsing of large distributed datasets. Bioinformatics. 2010;26(17):2204-7.

24. Davies RW, Flint J, Myers S, Mott R. Rapid genotype imputation from sequence without reference panels. Nature genetics. 2016;48(8):965-9.

25. Skotte L, Korneliussen TS, Albrechtsen A. Association testing for next-generation sequencing data using score statistics. Genet Epidemiol. 2012;36(5):430-7.

26. Korneliussen TS, Albrechtsen A, Nielsen R. ANGSD: Analysis of Next Generation Sequencing Data. BMC Bioinformatics. 2014;15:356.

27. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nature communications. 2017;8(1):1826.

28. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74.

29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.

30. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022.

31. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580-5.

32. Schmitt AD, Hu M, Jung I, Xu Z, Qiu Y, Tan CL, et al. A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. Cell reports. 2016;17(8):2042-59.

33. Giusti-Rodriguez PM, Sullivan PF. Using three-dimensional regulatory chromatin interactions from adult and fetal cortex to interpret genetic results for psychiatric disorders and cognitive traits. 2019:406330.

34. Akbarian S, Liu C, Knowles JA, Vaccarino FM, Farnham PJ, Crawford GE, et al. The PsychENCODE project. Nature neuroscience. 2015;18(12):1707-12.

35. Noguchi S, Arakawa T, Fukuda S, Furuno M, Hasegawa A, Hori F, et al.
FANTOM5 CAGE profiles of human and mouse samples. Scientific data.
2017;4:170112.
36. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation
method for the next generation of genome-wide association studies. PLoS Genet.
2009;5(6):e1000529.
37. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP:
the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308-11.
38. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The
mutational constraint spectrum quantified from variation in 141,456 humans. Nature.
2020;581(7809):434-43.
39. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than
replication-based analysis for two-stage genome-wide association studies. Nat Genet.
2006;38(2):209-13.
40. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD
Score regression distinguishes confounding from polygenicity in genome-wide
association studies. Nat Genet. 2015;47(3):291-5.
41. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, et al.
Systematic localization of common disease-associated variation in regulatory DNA.
Science. 2012;337(6099):1190-5.
42. Pasaniuc B, Rohland N, McLaren PJ, Garimella K, Zaitlen N, Li H, et al. Extremely
low-coverage sequencing and imputation increases power for genome-wide association
studies. Nature Genetics. 2012;44:631.
43. Wulf G, Ryo A, Liou Y-C, Lu KP. The prolyl isomerase Pin1 in breast development
and cancer. Breast Cancer Res. 2003;5(2):76-82.
44. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across
human tissues. Science (New York, NY). 2020;369(6509):1318-30.
45. Vora B, Wang A, Kosti I, Huang H, Paranjpe I, Woodruff TJ, et al. Meta-Analysis
of Maternal and Fetal Transcriptomic Data Elucidates the Role of Adaptive and Innate
Immunity in Preterm Birth. Front Immunol. 2018;9:993-.
46. Strauss JF, 3rd, Romero R, Gomez-Lopez N, Haymond-Thornburg H, Modi BP,
Teves ME, et al. Spontaneous preterm birth: advances toward the discovery of genetic
predisposition. American journal of obstetrics and gynecology. 2018;218(3):294-
314.e2.
47. Velez DR, Fortunato SJ, Thorsen P, Lombardi SJ, Williams SM, Menon R. Preterm
birth in Caucasians is associated with coagulation and inflammation pathway gene
variants. PloS one. 2008;3(9):e3283-e.
48. Sheikh IA, Ahmad E, Jamal MS, Rehan M, Assidi M, Tayubi IA, et al. Spontaneous
preterm birth and single nucleotide gene polymorphisms: a recent update. BMC
Genomics. 2016;17(Suppl 9):759.
49. Uzun A, Sharma S, Padbury J. A bioinformatics approach to preterm birth.
American journal of reproductive immunology (New York, NY : 1989).
2012;67(4):273-7.
50. Siffel C, Kistler KD, Lewis JFM, Sarda SP. Global incidence of bronchopulmonary

823 dysplasia among extremely preterm infants: a systematic literature review. The journal
824 of maternal-fetal & neonatal medicine : the official journal of the European Association
825 of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the
826 International Society of Perinatal Obstet. 2019:1-11.

827 51. Cai Y, Ma F, Qu L, Liu B, Xiong H, Ma Y, et al. Weighted Gene Co-expression
828 Network Analysis of Key Biomarkers Associated With Bronchopulmonary Dysplasia.
829 Front Genet. 2020;11:539292.

830 52. Villamor-Martinez E, Lubach GA, Rahim OM, Degraeuwe P, Zimmermann LJ,
831 Kramer BW, et al. Association of Histological and Clinical Chorioamnionitis With
832 Neonatal Sepsis Among Preterm Infants: A Systematic Review, Meta-Analysis, and
833 Meta-Regression. Front Immunol. 2020;11:972.

834 53. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, et al. Role of
835 ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005;26(5):943-50.

836 54. Schroder C, Witzel I, Muller V, Krenkel S, Wirtz RM, Janicke F, et al. Prognostic
837 value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J
838 Cancer Res Clin Oncol. 2011;137(8):1193-201.

839 55. Xu WH, Liu ZB, Yang C, Qin W, Shao ZM. Expression of dickkopf-1 and beta-
840 catenin related to the prognosis of breast cancer patients with triple negative phenotype.
841 PloS one. 2012;7(5):e37624.

842 56. Shin E, Lee Y, Koo JS. Differential expression of the epigenetic methylation-
843 related protein DNMT1 by breast cancer molecular subtype and stromal histology. J
844 Transl Med. 2016;14:87.

845 57. Wong KK. DNMT1: A key drug target in triple-negative breast cancer. Semin
846 Cancer Biol. 2020.

847 58. Robertson SA, Hutchinson MR, Rice KC, Chin PY, Moldenhauer LM, Stark MJ,
848 et al. Targeting Toll-like receptor-4 to tackle preterm birth and fetal inflammatory injury.
849 Clin Transl Immunology. 2020;9(4):e1121.

850 59. Zhang G, Srivastava A, Bacelis J, Juodakis J, Jacobsson B, Muglia LJ. Genetic
851 studies of gestational duration and preterm birth. Best Pract Res Clin Obstet Gynaecol.
852 2018;52:33-47.

853 60. Petraglia F, Imperatore A, Challis JR. Neuroendocrine mechanisms in pregnancy
854 and parturition. Endocr Rev. 2010;31(6):783-816.

855 61. Majzoub JA, McGregor JA, Lockwood CJ, Smith R, Taggart MS, Schulkin J. A
856 central theory of preterm and term labor: putative role for corticotropin-releasing
857 hormone. American journal of obstetrics and gynecology. 1999;180(1 Pt 3):S232-41.

858 62. Díaz-Pérez FI, Hiden U, Gauster M, Lang I, Konya V, Heinemann A, et al. Post-
859 transcriptional down regulation of ICAM-1 in feto-placental endothelium in GDM. Cell
860 adhesion & migration. 2016;10(1-2):18-27.

861 63. Chen X, Scholl TO. Maternal biomarkers of endothelial dysfunction and preterm
862 delivery. PloS one. 2014;9(1):e85716.

863 64. Labarrere CA, Bammerlin E, Hardin JW, Dicarlo HL. Intercellular adhesion
864 molecule-1 expression in massive chronic intervillositis: implications for the invasion
865 of maternal cells into fetal tissues. Placenta. 2014;35(5):311-7.

866 65. Kim SC, Lee JE, Kang SS, Yang HS, Kim SS, An BS. The regulation of oxytocin

and oxytocin receptor in human placenta according to gestational age. Journal of molecular endocrinology. 2017;59(3):235-43.

66. Keyser EA, Staat BC, Fausett MB, Shields AD. Pregnancy-associated breast cancer. Rev Obstet Gynecol. 2012;5(2):94-9.

67. Froehlich K, Schmidt A, Heger JI, Al-Kawlani B, Aberl CA, Jeschke U, et al. Breast cancer, placenta and pregnancy. Eur J Cancer. 2019;115:68-78.

906 **Figures**

Fig. 1. An overview of the analysis and benchmarking pipeline for ultra-low coverage WGS.

Fig. 2. Imputation accuracy at different coverages and sample sizes. The accuracies

of imputed genotype (a) or allele (b) were obtained by comparing with the known

genotypes in HG005. After using filter "INFO score ≥ 0.4 and HWE *p*-value > 1e-6",

the accuracies of imputed genotype (c) or allele (d).

Fig. 3. Performance of different imputation result filters. The accuracies of our
samples were calculated against the known genotypes in HG005. a, effect of INFO
score filtering cutoffs on genotype and allele accuracies. The imputation was conducted
by using 0.04x sequencing coverage of HG005 and with 16000 embryo samples. b,
effect of MAF cutoffs on genotype accuracy at multiple sequencing coverages. The
imputation was conducted through different sequencing coverages of HG005 with
16000 embryo samples.

Fig. 4. SNP-based genome-wide association on gestational age. a, Manhattan plot of the SNPs in GWAS. The red dash line represents the genome-wide significance level 4.515e-8. The SNP "rs946934582" with p value of 2.764e-144 is beyond the scale, thus hereby listed alone. The genes shown are linking with the candidate SNPs and position of the corresponding genomic risk loci. b, functional annotation and enrichment test result of the candidate SNPs in FUMA. c, a Venn diagram of the 166 genes that could be mapped to the 11 genomic risk loci by positional, eQTL and chromatin interaction strategies. d, a Circos plot of the chromatin interactions and eQTL mapping in the 11 genomic risk loci from eight chromosomes. The outer ring is chromosomes, the regions in blue denote genomic risk loci. The middle ring represents the mapped genes. The color of the gene symbols shows how they were mapped, eQTL in green, chromatin interaction in orange, and both eQTL and chromatin interaction in black. The inner ring shows the linking edges, eQTL in green, and chromatin interaction in orange. e, a summary of the 11 genomic risk loci.

Fig. 5. Comparison of the 166 genes mapped to 11 genomic risk loci with PTB and
infant disease. a, the 166 mapped genes were compared with 3 sets of reported PTB
genes including dbPTB from Sheikh et al. (48) and Uzun et al (49), PTB-merged from
5 resources (10), and PNAS-identified DEGs in 2019 (10) (see Additional file 1: Table
S8). b, a bar graph showing significantly enriched GO biological processes and KEGG
pathways based on the 50 PTB marker genes (see Additional file 1: Table S7). c-d,
heatmaps showing expression profiling and clusters of the PTB genes predicted from
GWAS under maternal PTB (c) and PTB infant with BPD and sepsis (d). The gene
expression data was extracted from the listed GSE accession numbers of NCBI/GEO.

Fig. 6. Associated analysis of the PTB-related genes in maternal and infant
subtypes. a, a gene co-expression network merging maternal and infant PTB subtypes.
b, a gene co-expression network merging maternal PTB and BPD of preterm infant. In
A and B, oval nodes represent PTB related genes predicted from GWAS using the 1,744
born embryo samples, rectangle nodes refer to the 50 top PTB markers summarized
from previously studies (Additional file 1: Table S7), involving immune or
inflammation (blue), apoptosis (yellow), angiogenesis (green), coagulation (purple) and
other biological processes (grey). Co-expressive edges (Pearson correlation p value <
0.01) linking nodes represent maternal (red), infant (blue) and both maternal and infant
(black). c, a graphic summary to illustrate gestational age's association with PTB, infant
disease and breast cancer.

Table 1. Genotype imputation performance with different filtering criteria

Filtering criteria	SNP number	Genotype accuracy	Allele accuracy
None	167814	0.584	0.758
Known SNP in 1000G reference panel	141161	0.578	0.751
INFO score ≥ 0.1	156835	0.591	0.771
INFO score ≥ 0.2	126331	0.618	0.794
INFO score ≥ 0.3	84932	0.656	0.815
INFO score ≥ 0.4	48176	0.7	0.834
MAF ≥ 0.05	162788	0.597	0.777
HWE p-value > 1e-9	84237	0.595	0.695
HWE p-value > 1e-6	77419	0.596	0.692
HWE p-value > 1e-3	65561	0.599	0.687
HWE p-value > 1e-6 and INFO score ≥ 0.1	68505	0.610	0.713
HWE p-value > 1e-6 and INFO score ≥ 0.2	55972	0.646	0.751
HWE p-value > 1e-6 and INFO score ≥ 0.3	42202	0.681	0.786
HWE p-value > 1e-6 and INFO score ≥ 0.4	28773	0.715	0.818

Totally 16,000 samples with an average of 0.04x sequencing coverage were used for imputation.

Table 2. Main mapped genes differentially expressed in PTB, infant disease and breast cancer

Genes mapped to risk loci	Overlapped No. with the reported PTB datasets	No. of DEGs detected in gene expression data						
		Maternal PTB	Infant PTB	Infant BPD	Infant sepsis	Breast cancer ER, PR	Breast cancer TNBC	Breast cancer HER2+
ICAM1	6	1(up)	2(up)	1(up)	1(up)	1(up),2(down)	2(up)	1(up)
CRHBP	5	2(up)	1(up)	1(up)				
OXTR	5	2(up)				1(up)	1(down)	
THBS4	3	1(down)	1(down)		1(up)	1(up)	2(down)	1(up),1(down)
EGR2	2	1(up)	1(up)	1(up)		1(up)	2(down)	2(down)
CNTLN	1	1(up)	1(up),1(down)		1(up)	1(down)		1(down)
MBL2	4		1(up)					
EMR1	2			1(up)				
PLAGL1	1	1(up)	2(up)		1(up)	2(down)	2(down)	2(down)
DKK1		2(up)	1(up)	1(down)		2(down)	3(up),1(down)	1(up),1(down)
GCNT4		1(down)	2(down)	1(down)	2(down)	1(up),2(down)	1(down)	1(down)
DNMT1		1(up)	1(up)				1(up)	1(up)
PIN1		1(down)	1(down)					

PTB related genes identified in our GWAS were compared with DEGs identified in published gene expression datasets (Additional file 1: Table S9). "up" and "down" indicate differentially overexpressed and underexpressed gene, respectively.